MA48863B1 - Protéines de fusion du récepteur tgf-bêta de type ii et utilisations associées - Google Patents

Protéines de fusion du récepteur tgf-bêta de type ii et utilisations associées

Info

Publication number
MA48863B1
MA48863B1 MA48863A MA48863A MA48863B1 MA 48863 B1 MA48863 B1 MA 48863B1 MA 48863 A MA48863 A MA 48863A MA 48863 A MA48863 A MA 48863A MA 48863 B1 MA48863 B1 MA 48863B1
Authority
MA
Morocco
Prior art keywords
tgf
fusion proteins
receptor type
beta receptor
related uses
Prior art date
Application number
MA48863A
Other languages
English (en)
Other versions
MA48863A (fr
Inventor
Ravindra Kumar
Dianne S Sako
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Priority claimed from PCT/US2018/030816 external-priority patent/WO2018204594A1/fr
Publication of MA48863A publication Critical patent/MA48863A/fr
Publication of MA48863B1 publication Critical patent/MA48863B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne, selon certains aspects, des polypeptides de fusion ?ßr?? Comprenant une partie hétérologue et une partie tronquée de liaison à un ligand du domaine extracellulaire du polypeptide ?ßr??, utiles pour antagoniser de manière sélective un ligand ?ßr??. L'invention concerne également des compositions et des procédés destinées à être utilisés pour traiter ou prévenir des troubles associés au tgfß.
MA48863A 2017-05-04 2018-05-03 Protéines de fusion du récepteur tgf-bêta de type ii et utilisations associées MA48863B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762501229P 2017-05-04 2017-05-04
PCT/US2018/030816 WO2018204594A1 (fr) 2017-05-04 2018-05-03 Protéines de fusion du récepteur tgf-bêta de type ii et utilisations associées

Publications (2)

Publication Number Publication Date
MA48863A MA48863A (fr) 2020-04-01
MA48863B1 true MA48863B1 (fr) 2023-08-31

Family

ID=88016828

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48863A MA48863B1 (fr) 2017-05-04 2018-05-03 Protéines de fusion du récepteur tgf-bêta de type ii et utilisations associées

Country Status (1)

Country Link
MA (1) MA48863B1 (fr)

Also Published As

Publication number Publication date
MA48863A (fr) 2020-04-01

Similar Documents

Publication Publication Date Title
MA34802B1 (fr) Nouvel antigène
EP4241848A3 (fr) Protéines de fusion du récepteur tgf-bêta de type ii et utilisations associées
MA39061A1 (fr) Modulateurs d'aplnr et leurs utilisations
WO2021041715A3 (fr) Compositions comprenant des mutations de fc d'igg et leurs utilisations
WO2019032945A9 (fr) Agent liant cd40 et utilisations associées
ZA202003953B (en) Activin receptor type iib variants and methods of use thereof
MA45125B1 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
AR099079A1 (es) Variantes de región fc con propiedades de unión de fcrn modificadas
SG10201908259WA (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
WO2021067863A3 (fr) Protéines de fusion fc hétérodimères d'il-12 ciblées
WO2018056821A8 (fr) Molécules de liaison qui modulent une activité biologique exprimée par une cellule
MA39254A1 (fr) Anticorps stables à affinité élevée et agrégatifs à base de domaines viraux vl et de dérivé de vhh
MA39313A1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
PE20090359A1 (es) Polipeptidos, dominios variables de anticuerpos y antagonistas
MA43763B1 (fr) Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'une infection vrs
GB201009493D0 (en) Modified recombinant factor viii and von willebrand factor and methods of use
EA201201047A1 (ru) Способы и композиции, в которых применяют слитые полипептиды fgf 23
CA3156704A1 (fr) Vaccin a proteines multi-domaines
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
RU2014153099A (ru) Терапевтическое средство или профилактическое средство против деменции
EP4674480A3 (fr) Procédés d'utilisation de variants du récepteur de l'activine de type ii
WO2003104282A8 (fr) Immunoadhesine comprenant un domaine de glycoproteine vi
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
MX2012001278A (es) Anticuerpos de dominio simple anti-receptor tgf-beta tipo ii.
BR112022005410A2 (pt) Métodos e composições compreendendo um anticorpo monoclonal anti-ctla4 com proteínas de célula hospedeira reduzidas e estabilidade de polissorbato 80 aumentada